Search Results

Orlando, FL (February 22, 2024) – Physicians at Orlando Health who pioneered a breakthrough protocol using tumor-infiltrating lymphocytes (TIL) to treat aggressive, late-stage melanoma and other advanced cancers is now available for patients.

Physicians at Orlando Health are pioneering a breakthrough protocol using tumor-infiltrating lymphocytes (TIL) to address aggressive, late-stage melanoma and other advanced cancers refractory to upfront immune checkpoint inhibitors.

Neuro-oncologists at Orlando Health Cancer Institute are effectively treating papillary craniopharyngioma positive for the BRAF mutation using novel targeted chemotherapy. Recently tested in clinical trials, the combination of BRAF inhibitor dabrafenib with selective mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor trametinib successfully shrinks tumors by targeting only the specific cancer cells expressing the BRAF mutation involved in regulating cell growth. And the best part: They are both oral agents and well-tolerated by the majority of patients.